Skip to main content

GENECAN Hospital cancer genetics platform

The GENECAN cancer molecular genetics platform is one of 28 platforms spread across the country supported by the National Cancer Institute . Its objective is to offer all patients in the region, regardless of the establishment where they are cared for, equal access to molecular tests in the face of cancer, allowing them to initiate the most appropriate targeted therapy.

It is common to the CHU Caen Normandie and the Center François Baclesse. It is backed by the Tumorotheque of Caen Basse-Normandie . Its activities are spread over 5 laboratories.

  • Activity

    Objective

    This platform aims to offer all patients in the former Basse-Normandie region, regardless of the establishment where they are cared for, equal access to molecular tests in the face of cancer, making it possible to initiate the most appropriate targeted therapy.

    This involves, for the pathologies concerned, analyzing certain biomarkers whose mutational status within the tumor is decisive for access to new therapies. These targeted therapies thus constitute “tailor-made” treatments adapted to the molecular characteristics of the patient's tumour.

  • Internal structures involved

    Biological platform